William Blair initiated coverage on Lucira Health
$LHDX
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Health Care
William Blair initiated coverage of Lucira Health with a rating of Outperform
Save time and jump to the most important pieces.
William Blair downgraded Lucira Health from Market Outperform to Market Perform
BofA Securities downgraded Lucira Health from Neutral to Underperform and set a new price target of $9.00
William Blair initiated coverage of Lucira Health with a rating of Outperform
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
4 - Lucira Health, Inc. (0001652724) (Issuer)
EMERYVILLE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the third quarter ended September 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $34.4 million for the third quarter of 2022, an increase of 130% over the third quarter of 2021.Executed a marketing agreement with Pfizer to increase awareness of the risks of COVID-19 and the availability of treatment. Partnered with telehealth marketplace, Sesame Care
EMERYVILLE, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. ("Lucira Health" or "Lucira"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, and a digital health platform that will connect patients with providers, today announced that the company will report third quarter 2022 financial results on, Monday, November 14th, 2022. Lucira's management will host a conference call and webcast at 1:30 p.m. PT / 4:30 p.m. ET that day to discuss the financial results and provide a corporate update. Conference Call and Webcast DetailsInvestors interested in listening to the conference call should reg
EMERYVILLE, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company focused on the development and commercialization of transformative and innovative infectious disease tests, today reported financial results for the second quarter ended June 30, 2022 and provided business updates. Recent Highlights Achieved net revenue of $26.1 million for the second quarter of 2022, an increase of 110% over the second quarter of 2021Received regulatory approval in Canada for the COVID-19 & Flu test with Self Test at Home indication and a full exemption by the New Zealand Ministry of Health for COVID-19 testSc
SC 13D/A - Lucira Health, Inc. (0001652724) (Subject)
Lab-quality results for both COVID-19 and Flu now available at home from one single testCOVID-19 and Flu have similar symptoms but different treatments, requiring a fast, differential test to access time-sensitive prescription treatment optionsLucira's COVID-19 & Flu Home Test demonstrated similar performance for COVID-19, Flu A and Flu B in head-to-head comparison study with highly sensitive lab-based PCR testsLucira seeks a strategic or financial partner for resumption of manufacturing and development of additional home diagnostic products EMERYVILLE, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health" or "Lucira"), a medical technology company,
EMERYVILLE, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Lucira Health, Inc. (NASDAQ:LHDX) ("Lucira Health," "Lucira" or the "Company"), a medical technology company, announced today that it has filed for protection under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, while continuing to support its customers during the Chapter 11 process. Lucira Health grew rapidly over the past several years as the COVID-19 pandemic spread throughout the world. Demand for the Company's COVID-19 test kits surged and the Company p
New partnership enables a free Sesame telehealth consultation with purchase of a Lucira at-home COVID-19 test, providing a full test-to-treat experience from the comfort of home, within two hours NEW YORK , Jan. 5, 2023 /PRNewswire/ -- Sesame, the company building a radically new healthcare system for uninsured Americans and those with high-deductible plans, and Lucira Health, Inc. ("Lucira Health" or "Lucira") today announced their national partnership to increase access to high-quality, convenient and affordable COVID-19 testing and treatment. Via Lucira Connect, a recently-launched virtual care platform, patients who purchase Lucira's COVID-19 Test can now easily learn about treatment opt
15-12G - Lucira Health, Inc. (0001652724) (Filer)
8-K - Lucira Health, Inc. (0001652724) (Filer)
NT 10-Q - Lucira Health, Inc. (0001652724) (Filer)
The FDA provided additional information about the agency's interactions and decisions regarding the emergency use authorization (EUA) of Lucira Health Inc's (OTC: LHDXQ) COVID-19 & Flu Home test. The statement comes due to concerns about the agency's length and timing of the EUA clearance and its bankruptcy filing, which said the delay in EUA financially hit the company. In an investor report, Lucira blamed the FDA's "protracted" authorization process for its combination Covid and flu at-home test. Lucira applied to the FDA for authorization of its novel test last May and expected to receive a thumbs-up by the end of summer before the flu season started. Canada authorized Lucira's test
Failures of Covid vaccine maker Novavax Inc (NASDAQ:NVAX) and diagnostic start-up Lucira Health Inc (NASDAQ:LHDX) show that companies often succeed or fail, owing to the whims of the government. Last week, while reporting Q4 earnings, Novavax raised doubts about its ability to remain in business and announced plans to cut spending. The Covid-19 vaccine was Novavax's first and only commercial product in its 36-year history, Wall Street Journal writes. However, the product flopped after successful trials thanks to regulatory delays and manufacturing hiccups. Operation Warp Speed awarded Novavax $1.6 billion to cover testing and manufacturing costs of its experimental vaccine in exchange f
Gainers ObsEva SA (NASDAQ:OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland. Altamira Therapeutics Ltd. (NASDAQ:CYTO) shares jumped 52.7% to $3.59 after the company said data from a recent peer-reviewed clinical study demonstrated Bentrio's superior nasal residence time and rheological properties. Lavoro Limited (NASDAQ:LVRO) gained 44.7% to $13.86. Lavoro and TPB Acquisition Corporation I announced completion of business combination. HUB Cyber Security (Israel) Ltd. (NASDAQ:HUBC) rose 36.6% to $1.71 after dipping 21% on Thursday. Seer, Inc. (NASDAQ:SEER) gained 35% to $5.68 a